| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/2159-8290.CD-12-0012 |
| P953 | full work available online at | https://aacrjournals.org/cancerdiscovery/article-pdf/2/3/214/1712704/214.pdf |
| https://cancerdiscovery.aacrjournals.org/content/candisc/2/3/214.full.pdf | ||
| P698 | PubMed publication ID | 22585993 |
| P50 | author | Pasi A Jänne | Q74766165 |
| Levi A Garraway | Q89916155 | ||
| P2860 | cites work | Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer | Q24309649 |
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance | Q24648017 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients | Q27653496 | ||
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M | Q27658766 | ||
| Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants | Q27660281 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. | Q27777367 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer | Q27851396 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor | Q27851455 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 | ||
| The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers | Q27851591 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. | Q27851684 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| Lineage dependency and lineage-survival oncogenes in human cancer | Q28253671 | ||
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
| Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation | Q28478937 | ||
| Topoisomerase levels determine chemotherapy responsein vitroandin vivo | Q29395563 | ||
| Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations | Q29614275 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number | Q29615128 | ||
| EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer | Q29616360 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor | Q33810574 | ||
| TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer | Q34100276 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia | Q34620246 | ||
| Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer | Q34778936 | ||
| Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. | Q34938204 | ||
| Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms | Q35204583 | ||
| MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS. | Q35443005 | ||
| The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research | Q36365560 | ||
| Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins | Q36726112 | ||
| Applying the discovery of the Philadelphia chromosome | Q36900109 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Targeted selection of recombinant clones through gene dosage effects | Q37510502 | ||
| Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib | Q39539475 | ||
| Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor | Q39554914 | ||
| Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | Q39568646 | ||
| FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. | Q39571776 | ||
| Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance | Q39782803 | ||
| Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors | Q39785355 | ||
| Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance | Q39850353 | ||
| Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. | Q39916367 | ||
| PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib | Q40033522 | ||
| Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line | Q40093771 | ||
| Evidence for multidrug-resistant cells in human tumor cell populations | Q40137710 | ||
| Dynamics of chronic myeloid leukaemia. | Q40403398 | ||
| Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma | Q42017054 | ||
| Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations | Q42742043 | ||
| Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia | Q43043759 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. | Q44155448 | ||
| A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia | Q44280538 | ||
| Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes | Q44356043 | ||
| Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. | Q44373949 | ||
| Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen | Q47975546 | ||
| Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia | Q52213829 | ||
| Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein | Q52829691 | ||
| MDR1 inhibition: less resistance or less relevance? | Q53948727 | ||
| Cross-resistance to alkylating agents in multiple myeloma | Q71788593 | ||
| Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial | Q72182720 | ||
| Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines | Q72561176 | ||
| Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma | Q73356015 | ||
| Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis | Q74114483 | ||
| Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia | Q80317123 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 214-226 | |
| P577 | publication date | 2012-02-28 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | Circumventing cancer drug resistance in the era of personalized medicine | |
| Circumventing Cancer Drug Resistance in the Era of Personalized Medicine | |||
| P478 | volume | 2 |
| Q34608734 | "Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance? |
| Q36360310 | 'Big data' approaches for novel anti-cancer drug discovery |
| Q53682041 | A Convergence-Based Framework for Cancer Drug Resistance |
| Q39155018 | A New View of Pathway-Driven Drug Resistance in Tumor Proliferation |
| Q37029832 | A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. |
| Q41908997 | A framework for understanding and targeting residual disease in oncogene-driven solid cancers |
| Q87832682 | A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer |
| Q35438912 | A functional landscape of resistance to ALK inhibition in lung cancer |
| Q37545380 | A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens |
| Q59615612 | A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer |
| Q48327570 | A new way to target p53-defective colorectal cancer |
| Q28817145 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner |
| Q36120408 | A simple gene set-based method accurately predicts the synergy of drug pairs |
| Q36740744 | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments |
| Q35004013 | Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature |
| Q38261107 | Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors |
| Q91935986 | Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2 |
| Q33586758 | Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy |
| Q38363739 | Adaptive stress signaling in targeted cancer therapy resistance |
| Q39278116 | Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer |
| Q90043616 | Animal Models to Study Cancer and Its Microenvironment |
| Q39214227 | Anti-Cancer Phytometabolites Targeting Cancer Stem Cells |
| Q36379354 | Anti-breast tumor activity of Eclipta extract in-vitro and in-vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis |
| Q38892678 | Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. |
| Q85564987 | Are Companion Diagnostics Useful? |
| Q34516773 | Attacking the supply wagons to starve cancer cells to death |
| Q28086785 | Autophagy in thyroid cancer: present knowledge and future perspectives |
| Q37362651 | Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides |
| Q35439316 | Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474 |
| Q64066117 | Benzyl isothiocyanate inhibits invasion and induces apoptosis via reducing S100A4 expression and increases PUMA expression in oral squamous cell carcinoma cells |
| Q37538158 | Biocomputing drug repurposing toward targeted therapies |
| Q89351018 | Biologically Relevant Heterogeneity: Metrics and Practical Insights |
| Q89537597 | Brevilin A Inhibits STAT3 Signaling and Induces ROS-Dependent Apoptosis, Mitochondrial Stress and Endoplasmic Reticulum Stress in MCF-7 Breast Cancer Cells |
| Q26995113 | Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib |
| Q39143850 | C-RAF Mutations Confer Resistance to RAF Inhibitors |
| Q37063329 | COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR. |
| Q38763117 | Cancer Therapeutics Following Newton's Third Law |
| Q55058388 | Cancer driver mutation prediction through Bayesian integration of multi-omic data. |
| Q27002537 | Cancer evolution: mathematical models and computational inference |
| Q37199267 | Cancer network activity associated with therapeutic response and synergism |
| Q52361534 | Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy |
| Q104611620 | CellBox: Interpretable Machine Learning for Perturbation Biology with Application to the Design of Cancer Combination Therapy |
| Q91639464 | Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase |
| Q64063299 | Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma |
| Q50147171 | Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. |
| Q35742353 | Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats |
| Q55070853 | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. |
| Q42553000 | Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma |
| Q34287101 | Combinatorial drug therapy for cancer in the post-genomic era. |
| Q35930811 | Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. |
| Q41881663 | Combined treatment with MET inhibitors and other therapies in lung cancer |
| Q34619336 | Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features |
| Q37644761 | Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds |
| Q36267411 | Continuous treatment with FTS confers resistance to apoptosis and affects autophagy |
| Q38628964 | Current state of biomarkers in ovarian cancer prognosis |
| Q38768617 | Cytotoxicity of Salvia miltiorrhiza Against Multidrug-Resistant Cancer Cells. |
| Q41241158 | DDA1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle. |
| Q92660599 | DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations |
| Q38725127 | DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents. |
| Q43979784 | Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. |
| Q33726782 | Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. |
| Q38117022 | Different strategies to overcome multidrug resistance in cancer |
| Q37258715 | Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs. |
| Q48125728 | Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen |
| Q99584571 | Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer |
| Q92581702 | Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer |
| Q27692033 | Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms |
| Q42832493 | Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. |
| Q35337927 | Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. |
| Q38891257 | Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view |
| Q42077285 | Dynamic BH3 profiling-poking cancer cells with a stick |
| Q64261762 | Dynamic Targeting in Cancer Treatment |
| Q90284575 | EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis |
| Q89514421 | ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis |
| Q38964435 | Emerging role of mTOR in the response to cancer therapeutics |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q50207484 | Epigenetic reprogramming: A key mechanism driving therapeutic resistance |
| Q38150749 | Epistatic interactions and drug response |
| Q46542092 | Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial |
| Q37255147 | Existing and emerging technologies for tumor genomic profiling |
| Q38966912 | FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor |
| Q35745004 | FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells |
| Q90208541 | Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy |
| Q37353087 | Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. |
| Q104745214 | Genetic screening for single-cell variability modulators driving therapy resistance |
| Q37746482 | Genome-Wide Screen Reveals sec21 Mutants of Saccharomyces cerevisiae Are Methotrexate-Resistant |
| Q90815056 | Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes |
| Q39012457 | HBXIP, a binding protein of HBx, regulates maintenance of the G2/M phase checkpoint induced by DNA damage and enhances sensitivity to doxorubicin-induced cytotoxicity |
| Q48218832 | Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions? |
| Q30384542 | Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. |
| Q38132855 | Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers |
| Q37274497 | Hsp90, an unlikely ally in the war on cancer |
| Q89456709 | Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy |
| Q28540918 | Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery |
| Q35949785 | Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems |
| Q27322456 | In vitro selection of mutant HDM2 resistant to Nutlin inhibition |
| Q57049536 | Is adaptive therapy natural? |
| Q48093822 | Just caring: assessing the ethical and economic costs of personalized medicine |
| Q92355958 | KRASG12C inhibition produces a driver-limited state revealing collateral dependencies |
| Q35770299 | Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. |
| Q35600324 | Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies |
| Q38094259 | Lessons from the Cancer Genome |
| Q28539118 | Leveraging systems biology approaches in clinical pharmacology |
| Q38987150 | Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells |
| Q90003849 | Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers |
| Q36422709 | Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer |
| Q28481370 | Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells |
| Q33597596 | MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines |
| Q37599935 | Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. |
| Q55043104 | Masitinib monotherapy in canine epitheliotropic lymphoma. |
| Q98726063 | Mechanisms of drug resistance mediated by long non-coding RNAs in non-small-cell lung cancer |
| Q41126784 | MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance |
| Q58923813 | MicroRNAs in Cancer Drug Resistance and Drug Sensitivity |
| Q56514276 | Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL |
| Q53746575 | Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm. |
| Q28081871 | Mouse models of colorectal cancer as preclinical models |
| Q94596807 | Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics |
| Q90694916 | Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors |
| Q50097295 | Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. |
| Q52666594 | New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. |
| Q41549887 | New perspectives of cobalt tris(bipyridine) system: anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers |
| Q34474239 | Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes |
| Q47197940 | Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma |
| Q35527068 | Novel molecular targets for urothelial carcinoma |
| Q57001160 | Objective assessment of cancer genes for drug discovery |
| Q38355156 | Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure |
| Q42321596 | Oncogenic regulation of tumor metabolic reprogramming |
| Q50301832 | Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer |
| Q42608173 | Open access to large scale datasets is needed to translate knowledge of cancer heterogeneity into better patient outcomes |
| Q64053762 | Optimal control nodes in disease-perturbed networks as targets for combination therapy |
| Q99558636 | Overcoming Resistance to Drugs Targeting KRASG12C Mutation |
| Q89705143 | Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy |
| Q53705802 | PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. |
| Q64897044 | Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine. |
| Q52604587 | Performance comparison of three DNA extraction kits on human whole-exome data from formalin-fixed paraffin-embedded normal and tumor samples |
| Q26866517 | Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance |
| Q35602861 | Personalized genomic analyses for cancer mutation discovery and interpretation |
| Q57177486 | Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective |
| Q38232150 | Personalized oncology: genomic screening in phase 1. |
| Q34489987 | Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells |
| Q48786945 | Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution |
| Q38776411 | Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma |
| Q92533682 | Polytherapy and Targeted Cancer Drug Resistance |
| Q36392035 | Potential mechanisms of resistance to venetoclax and strategies to circumvent it. |
| Q27322080 | Preclinical mouse cancer models: a maze of opportunities and challenges |
| Q57811412 | Predicting Tumor Sensitivity to Chemotherapeutic Drugs in Oral Squamous Cell Carcinoma Patients |
| Q39032726 | Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics |
| Q27015224 | Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies |
| Q89824200 | Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms |
| Q37702589 | Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells |
| Q42059322 | RAS signaling in ALK fusion lung cancer |
| Q42910360 | RAS-MAPK in ALK targeted therapy resistance |
| Q42729864 | RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer |
| Q38322277 | RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop |
| Q40961495 | Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. |
| Q37514977 | Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology |
| Q45347095 | Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance |
| Q26797285 | Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models |
| Q36283038 | Recurrent oral cancer: current and emerging therapeutic approaches. |
| Q92203211 | Regulostat Inferelator: a novel network biology platform to uncover molecular devices that predetermine cellular response phenotypes |
| Q35412202 | Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. |
| Q37661161 | Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity |
| Q27853080 | Response and acquired resistance to everolimus in anaplastic thyroid cancer |
| Q38172322 | Rethinking the war on cancer |
| Q28553891 | Reverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target Interactions |
| Q36386428 | Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives |
| Q54998724 | S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. |
| Q38536624 | STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance |
| Q37305642 | Single-cell intracellular nano-pH probes. |
| Q90412592 | Spotlight on AKT: Current Therapeutic Challenges |
| Q92215319 | Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations |
| Q37238675 | Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma |
| Q42061069 | Super Aqueous Solubility of Albendazole in β-Cyclodextrin for Parenteral Application in Cancer therapy |
| Q38721555 | Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer |
| Q89286232 | Synthesis, docking and anticancer activity of azo-linked hybrids of 1,3,4-thia-/oxadiazoles with cyclic imides |
| Q28076462 | Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment |
| Q33725972 | Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. |
| Q39103431 | Targeting ALK: Precision Medicine Takes on Drug Resistance |
| Q37395800 | Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways |
| Q37506032 | Targeting the LKB1 tumor suppressor |
| Q37317194 | Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells |
| Q38601568 | Targeting tumor suppressor genes for cancer therapy |
| Q57811691 | TdIF1: a putative oncogene in NSCLC tumor progression |
| Q40630001 | The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors |
| Q38748127 | The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. |
| Q91737758 | The Role Of Circulating Tumor DNA In Therapeutic Resistance |
| Q64064411 | The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway |
| Q55009579 | The clinical impact of using complex molecular profiling strategies in routine oncology practice. |
| Q53700123 | The emerging clinical relevance of genomics in cancer medicine |
| Q37536556 | The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation |
| Q26998894 | The next steps in next-gen sequencing of cancer genomes |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q38097382 | The war on cancer: are we winning? |
| Q90328159 | Towards rapid prediction of drug-resistant cancer cell phenotypes: single cell mass spectrometry combined with machine learning |
| Q54967334 | Treating ALK-positive non-small cell lung cancer. |
| Q38275060 | Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer |
| Q64100347 | Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment |
| Q29617990 | Tumour heterogeneity and cancer cell plasticity |
| Q33690336 | Understanding Drug Resistance in Breast Cancer with Mathematical Oncology |
| Q26825780 | What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway |
| Q27853005 | Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine |
| Q43632068 | YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. |
| Q35200483 | ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. |
| Q91923945 | mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro |
| Q42378326 | mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition |
| Q38881549 | miRNAs: mediators of ErbB family targeted therapy resistance |
Search more.